Abstract

Microsatellite-instable (MSI), a predictive biomarker for immune checkpoint blockade (ICB) response, is caused by mismatch repair deficiency (MMRd) that occurs through genetic or epigenetic silencing of MMR genes. Here, we report a mechanism of MMRd and demonstrate that protein phosphatase 2A (PP2A) deletion or inactivation converts cold microsatellite-stable (MSS) into MSI tumours through two orthogonal pathways: (i) by increasing retinoblastoma protein phosphorylation that leads to E2F and DNMT3A/3B expression with subsequent DNA methylation, and (ii) by increasing histone deacetylase (HDAC)2 phosphorylation that subsequently decreases H3K9ac levels and histone acetylation, which induces epigenetic silencing of MLH1. In mouse models of MSS and MSI colorectal cancers, triple-negative breast cancer and pancreatic cancer, PP2A inhibition triggers neoantigen production, cytotoxic T cell infiltration and ICB sensitization. Human cancer cell lines and tissue array effectively confirm these signaling pathways. These data indicate the dual involvement of PP2A inactivation in silencing MLH1 and inducing MSI.

Microsatellite instability (MSI), caused by deficiency of the DNA mismatch repair system, has been associated with improved response to immune checkpoint blockade (ICB). Here the authors show that inactivation of protein phosphatase 2A induces a MSI status, promoting cytotoxic T cell infiltration and response to ICB in pre-clinical cancer models.

Details

Title
Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production and immune response
Author
Yu-Ting, Yen 1 ; May, Chien 1 ; Pei-Yi, Wu 1 ; Chi-Chang, Ho 1 ; Chun-Te, Ho 1 ; Huang, Kevin Chih-Yang 2   VIAFID ORCID Logo  ; Chiang Shu-Fen 3 ; Clifford, Chao K S 4 ; Chen, William Tzu-Liang 5 ; Hung Shih-Chieh 6   VIAFID ORCID Logo 

 China Medical University, Drug Development Center, Institute of New Drug Development, Taichung, Taiwan (GRID:grid.254145.3) (ISNI:0000 0001 0083 6092); China Medical University Hospital, Integrative Stem Cell Center, Taichung, Taiwan (GRID:grid.411508.9) (ISNI:0000 0004 0572 9415) 
 China Medical University, Department of Biomedical Imaging and Radiological Science, Taichung, Taiwan (GRID:grid.254145.3) (ISNI:0000 0001 0083 6092); China Medical University, Translation Research Core, China Medical University Hospital, Taichung, Taiwan (GRID:grid.254145.3) (ISNI:0000 0001 0083 6092) 
 China Medical University, Proton Therapy and Science Center, China Medical University Hospital, Taichung, ROC (GRID:grid.254145.3) (ISNI:0000 0001 0083 6092); Ministry of Health and Welfare, Lab of Precision Medicine, Feng-Yuan Hospital, Taichung, Taiwan (GRID:grid.454740.6) 
 China Medical University, Proton Therapy and Science Center, China Medical University Hospital, Taichung, ROC (GRID:grid.254145.3) (ISNI:0000 0001 0083 6092) 
 China Medical University, Department of Colorectal Surgery, China Medical University Hospital, Taichung, Taiwan (GRID:grid.254145.3) (ISNI:0000 0001 0083 6092); China Medical University, Department of Colorectal Surgery, China Medical University HsinChu Hospital, HsinChu, Taiwan (GRID:grid.254145.3) (ISNI:0000 0001 0083 6092) 
 China Medical University, Drug Development Center, Institute of New Drug Development, Taichung, Taiwan (GRID:grid.254145.3) (ISNI:0000 0001 0083 6092); China Medical University Hospital, Integrative Stem Cell Center, Taichung, Taiwan (GRID:grid.411508.9) (ISNI:0000 0004 0572 9415); China Medical University Hospital, Department of Orthopaedics, Taichung, Taiwan (GRID:grid.411508.9) (ISNI:0000 0004 0572 9415) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2610237034
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.